| Previous Close | 65.60 |
| Open | 65.63 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 65.07 - 65.70 |
| 52 Week Range | 58.29 - 66.80 |
| Volume | 7,465,921 |
| Avg. Volume | 7,856,921 |
| Market Cap | 177.63B |
| Beta | 0.94 |
| PE Ratio (TTM) | 35.26 |
| EPS (TTM) | 1.85 |
| Earnings Date | Oct 27, 2017 |
| Dividend & Yield | 1.88 (2.85%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | 70.11 |
- 24/7 Wall St.•23 hours ago
Apple, UnitedHealth Weigh on DJIA Friday
Apple, UnitedHealth, Walmart, and Merck led the losers among the Dow 30 stocks on Friday.
- Business Wire•yesterday
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)
Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA® , the company’s anti-PD-1 therapy, for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 as determined by an FDA-approved test, with ...
- Motley Fool•yesterday
AstraZeneca Stock Upgraded: What You Need to Know
Bernstein sees opportunity in a buyout target.
